Effect of Clazosentan in Patients with Aneurysmal Subarachnoid Hemorrhage: A Meta-Analysis of Randomized Controlled Trials

Xiang Wang1*, Yi-Ming Li1*, Wei-Qing Li2, Cheng-Guang Huang1*, Yi-Cheng Lu1, Li-Jun Hou1*

1 Department of Neurosurgery, Second Military Medical University, Changzheng Hospital, Shanghai, China; 2 Department of Pathology, Second Military Medical University, Changzheng Hospital, Shanghai, China

Abstract

Background: Cerebral vasospasm is the most important potentially treatable cause of mortality and morbidity following aneurysmal subarachnoid hemorrhage (aSAH). Clazosentan, a selective endothelin receptor antagonist, has been suggested to help reduce the incidence of vasospasm in patients with aSAH. However, the results were controversial in previous trials. This meta-analysis attempts to assess the effect of clazosentan in patients with aSAH.

Methodology/Principal Findings: We systematically searched Pubmed, Embase, and the Cochrane Library from their inception until June, 2012. All randomized controlled trials (RCTs) related to the effect of clazosentan in aSAH were included. The primary outcomes included the incidence of angiographic vasospasm, new cerebral infarction (NCI), delayed ischemic neurological deficits (DIND), and vasospasm-related morbidity/mortality (M/M); the second outcomes included the occurrence of rescue therapy, all-cause mortality, and poor outcome. 4 RCTs were included with a total of 2156 patients. The risk of angiographic vasospasm (relative risk [RR] = 0.58; 95% CI, 0.48 to 0.71), DIND (RR = 0.76; 95% CI, 0.62 to 0.92), and vasospasm-related M/M (RR = 0.80; 95% CI, 0.67 to 0.96) were statistically significantly reduced in the clazosentan group. Patients treated with clazosentan had a reduced occurrence of rescue therapy (RR = 0.62; 95% CI, 0.49 to 0.79). However, no statistically significant effects were observed in NCI (RR = 0.74; 95% CI, 0.52 to 1.04), mortality (RR = 1.03; 95% CI, 0.71 to 1.49), and poor outcome (RR = 1.12; 95% CI, 0.96 to 1.30).

Conclusions/Significance: Our pooling data supports that clazosentan is probably effective in preventing the occurrence of angiographic vasospasm, vasospasm-related DIND, vasospasm related M/M, and rescue therapy. However, no evidence lends significant supports to the benefits of clazosentan in decreasing the occurrence of NCI, mortality or improving the functional outcome.

Introduction

Despite significant advances in treatment of aneurysmal subarachnoid hemorrhage (aSAH), the outcome remains poor. At the very least, a quarter patients with aSAH died, and roughly half of the survivors had persistent neurological deficits [1]. Cerebral vasospasm is the most important potentially treatable cause of mortality and morbidity following aSAH [2]. It is recognized as the primary cause of delayed cerebral ischemia (DCI) and the consequent delayed ischemic neurological deficits (DIND) [2].

So far, the pathogenesis of cerebral vasospasm remains incompletely understood. Current management of cerebral vasospasm, including calcium channel antagonists, statins, magnesium sulphate, triple-H therapy (hypervolemia, hypertension, and hemodilution), and rescue therapy with angioplasty and intra-arterial infusion of vasodilators, still shows variable effectiveness [1].

Recently, it has been indicated that endothelin-1 (ET) plays a critical role in the pathogenesis of vasospasm [3]. Clazosentan, the first nonpeptide selective ETA receptor antagonist, was thought to be a “magic bullet” to inhibit endothelin-mediating vasospasm [2]. Some trials about the effect of clazosentan in aSAH have been conducted but with inconsistent conclusions. For instance, some investigators suggested that clazosentan decreased the severity and the incidence of vasospasm [4,5], or the vasospasm-related morbidity/mortality (M/M) [5,6], while others argued against that [7]. Thus, we performed this meta-analysis of clazosentan treatment after aSAH, aiming to determine the positive effects and associated adverse effect (AE) of clazosentan treating aSAH.
Methods

Search Strategy
The overview of RCTs was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) statement [8]. We systematically searched Pubmed, Embase, and the Cochrane Library from their inception until June 2012 without language restriction, and identified all RCTs related to the effects of clazosentan in aSAH. We used the following search keywords: “clazosentan”, “intracranial aneurysm”, “subarachnoid hemorrhage”, “vasospasm”, and “randomized controlled trial”. Additionally, we manually searched the references of selective papers to identify additional potentially eligible studies.

Selection Criteria
Studies meeting the following criteria were selected: randomized controlled trial; patients with aSAH; treatment of clazosentan compared with placebo, randomly assigned following aSAH; outcomes were reported as vasospasm, vasospasm-related complications, or the functional outcome. In case of multiple reports on the same trial, the one with more comprehensive information was selected for meta-analysis.

Data Extraction
Two assessors (XW and YML) independently reviewed the full manuscripts of eligible studies. Data were extracted independently in standardized data-collection forms. Extracted data included first author’s name; year of publication; sample size; patients’ characteristics (mean age, gender); surgical intervention; treatment arms; dose; starting time of treatment; treatment duration; rescue therapy; adverse effects; primary and secondary outcomes. Any discrepancy was resolved by discussion or a third author (CGH). Selected RCTs were critically appraised using the Jadad scale, which scores studies’ description of randomization (2 points), blinding (2 points) and attrition information (1 point) [9]. We also assessed whether studies adequately reported concealment of treatment allocation or intention-to-treat (ITT) analysis.

Study Outcomes
The outcomes of interest included the occurrence of vasospasm, new cerebral infarction (NCI), DIND, and vasospasm-related morbidity and mortality (MM), which represented the primary

Figure 1. The flowchart shows the selection of studies for meta-analysis.
doi:10.1371/journal.pone.0047778.g001
The secondary outcomes were indicated by all-cause mortality and the functional outcome. Vasopasm was defined as focal or generalized reduction of the arterial caliber in cerebral angiogram (angiographic vasospasm). The term “delayed cerebral ischemia (DCI)” was abandoned due to controversial definitions. Cerebral infarction and clinical deterioration due to DCI have been suggested to be respectively assessed [10,11]. Accordingly, we predefined vasospasm-related new cerebral infarction (NCI), detected by the postoperative CT scan, as one of the primary outcomes. DIND was defined as a decrease of ≥2 points in the modified Glasgow Coma Scale (GCS) or an increase of ≥2 points in the abbreviated National Institutes of Health stroke scale (NIHSS) lasting for at least 2 h. For patients in whom neurological scales were not assessable, DIND was defined as administration of rescue therapy. Rescue therapy included initiation or increase in dose of an intravenous vasopressor with or without fluid therapy, or intra-arterial vasodilator, or balloon angioplasty. Vasospasm-related M/M was defined by at least one of the following events: death, NCI, DIND, and rescue therapy. Poor outcome was defined as scores of 1–4 in the Glasgow Outcome Scale (GOS) [12].

Subgroup Analyses
The subgroup analyses mainly included age, sex, the World Federation of Neurological Surgeons (WFNS) scale, clot size, and dosage of clazosentan, aiming to evaluate their roles in reducing the risk of vasospasm related M/M. Age was dichotomously divided into <50, 50–60, and >60. Sex was dichotomously divided into male and female. The WFNS scale had been widely used to assess the initial clinical and radiologic features of aSAH with 5 grades of severity, which was dichotomously divided into a lower grade (I–II) and a higher grade (III–IV). The higher the score was, the worse the prognosis would be [13]. The clot sizes included four types: diffuse thick, diffuse thin, local thick, and local thin. The diffuse thick type was suggested to be one of predominant predictive factors in aSAH [14]. So, it was independently analyzed from other three types. Dosages of the drug were analyzed based on administered doses in different trials.

Statistical Analysis
All outcome variables were dichotomous, as well as the reported AE variables. Review Manager 5.1.7 (Cochrane Collaboration, 2012) was used to process these data. Data with only relative risk (RR) and 95% CI extracted were pooled with Stata 12.0 (Stata Corporation, College Station, TX, USA). RR estimates were calculated to show the effect sizes, with either fixed-effects model or random-effects model used. P>0.10 in the χ² test and I²<25% were interpreted as low-level heterogeneity. When significant heterogeneity was absent, the fixed-effects model was employed; otherwise, the random-effects model was used. The statistical uncertainty was expressed in 95% CIs. The publication bias was assessed through funnel plots. A two-tailed P<0.05 was deemed statistically significant.

Results
Characteristics of Selected Studies
From the 272 initial records, 16 relevant articles were found. Further, 12 studies were excluded, including one preliminary RCT by the same investigators [3], one pharmacological RCT [15], and 10 post-hoc studies of CONSCIOUS-1 trial. 4 RCTs were included in the meta-analysis, with 2156 patients totally (1472 with clazosentan, 684 with placebo) (Figure 1) [4,5,6,7]. The characteristics of these studies were listed in Table 1. All RCTs were of

| Characteristics of RCTs Assessing the Effects of Clazosentan in aSAH and Critical Appraisal of RCTs. | Age | Treatment | No. of Eligibility, Female | Sex, % | Intervention | Treatment Arms | Jadad Score | ITT Analysis | Study/Year | Treatment Duration | Primary Outcome | Secondary Outcome | Secondary Outcome | Secondary Outcome | Secondary Outcome |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | | | | | | | | | | | | | | |
| Vajkoczy et al. 2005 | 32 | 18–65 | 64.7 | Clipping | Clazosentan (0.2 mg/kg/h) vs placebo | 48 h Max 14d | Angiographic vasospasm | NCI | Yes | Vajkoczy et al. 2005 | 32 | 18–65 | 64.7 | Clipping | Clazosentan (0.2 mg/kg/h) vs placebo | 48 h Max 14d | Angiographic vasospasm | NCI | Yes |
| Macdonald et al. 2008 | 409 | 18–71 | 70.7 | Clipping or coiling | Clazosentan (1 mg/h, 5 mg/h, 15 mg/h) vs placebo | 56 h Max 14d | Angiographic vasospasm | DIND; NCI; Rescue therapy; GOSE; AEs | No (185:224) | Macdonald et al. 2008 | 409 | 18–71 | 70.7 | Clipping or coiling | Clazosentan (1 mg/h, 5 mg/h, 15 mg/h) vs placebo | 56 h Max 14d | Angiographic vasospasm | DIND; NCI; Rescue therapy; GOSE; AEs | No (185:224) |
| Macdonald et al. 2011 | 1147 | 18–75 | 67.6 | Clipping | Clazosentan (5 mg/h) vs placebo | 56 h Max 14d | Vasospasm-related M/M | GOSE | Yes | Macdonald et al. 2011 | 1147 | 18–75 | 67.6 | Clipping | Clazosentan (5 mg/h) vs placebo | 56 h Max 14d | Vasospasm-related M/M | GOSE | Yes |
| Macdonald et al. 2012 | 571 | 19–76 | 69.9 | Coiling | Clazosentan (5 mg/h, 15 mg/h) vs placebo | 56 h Max 14d | Vasospasm-related M/M | M/M | No | Macdonald et al. 2012 | 571 | 19–76 | 69.9 | Coiling | Clazosentan (5 mg/h, 15 mg/h) vs placebo | 56 h Max 14d | Vasospasm-related M/M | M/M | No |

Abbreviations: AEs, adverse effects; DIND, Delayed ischemic neurological deficit; GOSE, Glasgow Outcome Scores Extended; ITT, intention-to-treat; M/M, morbidity/mortality; NCI, new cerebral infarction.
high methodological quality with a satisfying Jadad score. 2 studies were performed on an ITT basis (Table 1) [4,7].

**Primary Outcomes**

**Angiographic vasospasm.** Data of the occurrence of angiographic vasospasm were available in 2 trials, with a total of 441 patients (328 with clazosentan, 113 with placebo) [4,5]. The occurrence of angiographic vasospasm was significantly reduced in the clazosentan group compared with the placebo one (RR = 0.58; 95% CI, 0.48 to 0.71; P = 0.05; Figure 2A). The number needed to treat (NNT) for this outcome was 3.4. Data did not indicate heterogeneity (I² = 0%).

**NCI.** NCI was reported in all trials, with a total of 2156 patients (1472 with clazosentan, 684 with placebo) [4,5,6,7].
Heterogeneity was observed ($P=0.15$) and thus the random-effects model was employed. The prevalence of NCI was reduced in the clazosentan group compared with that in the placebo group (RR = 0.74; 95% CI, 0.52 to 1.04, Figure 2B). The NNT was 30.6. However, statistically significance was not observed ($P > 0.05$).

**DIND.** DIND was reported in the CONSCIOUS trials, with a total of 2127 patients (1459 with clazosentan, 668 with placebo) [5,6,7]. The occurrence of DIND was significantly reduced in the clazosentan group than that in the placebo group (RR = 0.76; 95% CI, 0.62 to 0.92; $P < 0.05$; Figure 2C). The NNT was 21.4. Significant heterogeneity was not revealed ($P = 0.56$).

**Vasospasm-related morbidity/mortality.** The overall vasospasm-related M/M was assessed in 2 trials, with a total of 1718 patients (1146 with clazosentan, 572 with placebo) [6,7]. Patients treated with clazosentan had a statistically significant reduction in the occurrence of vasospasm-related M/M (RR = 0.80; 95% CI, 0.67 to 0.96; $P < 0.05$; Figure 2D). The NNT was 19.6. Significant heterogeneity was not revealed ($P = 0.56$).

**Secondary Outcomes**

**Functional outcome.** In the analyses of poor outcome, 3 CONSCIOUS trials were included [5,6,7]. Poor outcome was accordantly defined as GOSE$\geq 4$ at week 12. Totally, 2127 patients were available (1459 with clazosentan, 668 with placebo). The overall RR of clazosentan therapy for poor outcome was 1.12 (95% CI, 0.96 to 1.30; Figure 3A). Heterogeneity was not significant ($P = 0.50$).

**Mortality.** All trials reported all-cause death after aSAH [4,5,6,7]. Data were available for 2161 patients (861/1475 died in the clazosentan group, 40/686 died in the placebo group). There was no significant difference between the two groups (RR = 1.03; 95% CI, 0.71 to 1.49; $P > 0.05$; Figure 3B). Significant heterogeneity was not observed ($P = 0.84$).

**Rescue therapy.** Rescue therapy was investigated in the CONSCIOUS-2, 3 trials, 1718 patients totally (1146 with clazosentan, 572 with placebo) [6,7]. Patients treated with clazosentan had a reduced occurrence of rescue therapy (RR = 0.62; 95% CI, 0.49 to 0.79; $P < 0.01$; Figure 3C). Significant heterogeneity was not found ($P = 0.27$).
Safety

The AEs of clazosentan were listed in all studies, which mainly included hypotension, lung complications, cardiovascular complications, and anemia. Overall, the clazosentan group had a statistically significant increase in AEs compared with the placebo group (RR = 1.59; 95% CI, 1.43 to 1.77; P < 0.01).

### Figure 4. Forest plot shows the incidence of adverse effects in patients assigned to clazosentan versus placebo.

doi:10.1371/journal.pone.0047778.g004

| Study or Subgroup | Clazosentan | Placebo | Risk Ratio M-H, Fixed, 95% CI | Risk Ratio M-H, Fixed, 95% CI |
|-------------------|-------------|---------|-----------------------------|-----------------------------|
| **Hypotension**   |             |         |                             |                             |
| MacDonald 2008    | 30          | 131     | 3.07 [0.96, 9.83]           |                             |
| MacDonald 2011    | 95          | 764     | 2.80 [1.70, 4.62]           |                             |
| MacDonald 2012    | 51          | 382     | 1.94 [1.08, 3.48]           |                             |
| Vajkeczy 2005     | 1           | 15      | 0.57 [0.06, 5.64]           |                             |
| Subtotal (95% CI) | 1474        | 685     | 2.42 [1.69, 3.45]           |                             |
| Total events      | 177         | 35      |                             |                             |
| Heterogeneity: Chi² = 2.57, df = 3 (P = 0.46); I² = 0% | Test for overall effect: Z = 4.87 (P < 0.00001) |

| **Central nervous system** | Clazosentan | Placebo | Risk Ratio M-H, Fixed, 95% CI | Risk Ratio M-H, Fixed, 95% CI |
|-----------------------------|-------------|---------|-----------------------------|-----------------------------|
| MacDonald 2008              | 30          | 764     | 1.25 [0.65, 2.42]           |                             |
| MacDonald 2011              | 14          | 362     | 1.39 [0.51, 3.79]           |                             |
| Vajkeczy 2005               | 4           | 15      | 0.57 [0.21, 1.51]           |                             |
| Subtotal (95% CI)           | 1161        | 589     | 1.11 [0.69, 1.79]           |                             |
| Total events                | 48          | 25      |                             |                             |
| Heterogeneity: Chi² = 2.13, df = 2 (P = 0.34); I² = 6% | Test for overall effect: Z = 0.43 (P = 0.66) |

| **Respiratory system**      | Clazosentan | Placebo | Risk Ratio M-H, Fixed, 95% CI | Risk Ratio M-H, Fixed, 95% CI |
|-----------------------------|-------------|---------|-----------------------------|-----------------------------|
| MacDonald 2008              | 132         | 313     | 1.56 [1.09, 2.22]           |                             |
| MacDonald 2011              | 260         | 764     | 1.92 [1.51, 2.43]           |                             |
| MacDonald 2012              | 140         | 362     | 1.73 [1.28, 2.35]           |                             |
| Vajkeczy 2005               | 2           | 15      | 2.27 [0.23, 22.56]          |                             |
| Subtotal (95% CI)           | 1474        | 685     | 1.79 [1.52, 2.11]           |                             |
| Total events                | 534         | 135     |                             |                             |
| Heterogeneity: Chi² = 1.00, df = 3 (P = 0.80); I² = 0% | Test for overall effect: Z = 6.90 (P < 0.00001) |

| **Cardiovascular system**   | Clazosentan | Placebo | Risk Ratio M-H, Fixed, 95% CI | Risk Ratio M-H, Fixed, 95% CI |
|-----------------------------|-------------|---------|-----------------------------|-----------------------------|
| MacDonald 2011              | 109         | 764     | 1.21 [0.88, 1.68]           |                             |
| MacDonald 2012              | 50          | 362     | 0.95 [0.61, 1.48]           |                             |
| Vajkeczy 2005               | 4           | 15      | 1.13 [0.34, 3.76]           |                             |
| Subtotal (95% CI)           | 1161        | 589     | 1.12 [0.87, 1.44]           |                             |
| Total events                | 163         | 75      |                             |                             |
| Heterogeneity: Chi² = 0.76, df = 2 (P = 0.68); I² = 0% | Test for overall effect: Z = 0.86 (P = 0.39) |

| **Anemia**                  | Clazosentan | Placebo | Risk Ratio M-H, Fixed, 95% CI | Risk Ratio M-H, Fixed, 95% CI |
|-----------------------------|-------------|---------|-----------------------------|-----------------------------|
| MacDonald 2008              | 78          | 313     | 1.50 [0.92, 2.43]           |                             |
| MacDonald 2011              | 171         | 764     | 1.50 [1.14, 1.98]           |                             |
| MacDonald 2012              | 49          | 382     | 1.35 [0.81, 2.25]           |                             |
| Subtotal (95% CI)           | 1459        | 668     | 1.47 [1.19, 1.83]           |                             |
| Total events                | 298         | 91      |                             |                             |
| Heterogeneity: Chi² = 0.14, df = 2 (P = 0.93); I² = 0% | Test for overall effect: Z = 3.51 (P = 0.0005) |

| Total (95% CI)              | 6729        | 3216    | 1.59 [1.43, 1.77]           |                             |
| Total events                | 1220        | 361     |                             |                             |
| Heterogeneity: Chi² = 23.76, df = 16 (P = 0.09); I² = 33% | Test for overall effect: Z = 8.42 (P < 0.00001) |
| Test for subanterior differences: Chi² = 17.15, df = 4 (P = 0.002); I² = 76.7% | |
A dose-dependent risk of AEs was not observed (Figure 5).

**Table 2.** Subgroup analyses with pooling RR and 95% CI of CONSCIOUS-2,3 trials.

| Sex | RR   | 95% CI | Heterogeneity test |
|-----|------|--------|--------------------|
| Men | 0.82 | 0.58–1.18 | 0.574 |
| Women | **0.79** | **0.63–0.99** | 0.506 |
| Age (y) | | | |
| <50 | 0.72 | **0.52–0.99** | 0.726 |
| 50–60 | 0.87 | 0.62–1.20 | 0.225 |
| ≥60 | 0.80 | 0.55–1.15 | 0.818 |
| WFNS | | | |
| WFNS I,II* | 0.73 | 0.46–1.18 | 0.065 |
| WFNS III,IV,V* | 0.82 | 0.53–1.26 | 0.094 |
| Clot size | | | |
| Diffuse thick | **0.75** | **0.61–0.93** | 1.000 |
| Non-diffuse | 0.78 | 0.53–1.15 | 0.271 |

*Data pooled with random effects analysis due to heterogeneity. Significant effects are shown in bold.

doi:10.1371/journal.pone.0047778.t002

**Figure 5.** Forest plot on the adverse effects of 5 mg/h and 15 mg/h clazosentan respectively, with subgroup analyses.
doi:10.1371/journal.pone.0047778.g005

**Subgroup Analyses**

Data of subgroup analyses were available in CONSCIOUS-2, 3 trials, with only RR and 95% CI extracted. They were pooled with Stata software. It revealed that age<50, female, and diffuse thick clot had statistically significances in decreasing the incidence of vasospasm related M/M (Table 2). The CONSCIOUS-1,3 trial compared clazosentan in different doses with placebo in the occurrence of vasospasm-related M/M. Pooling data suggested that clazosentan in 1 mg/h had no significant reduction in vasospasm-related M/M, while when the dose was in 5 mg/h or 15 mg/h, statistically significant decreasing was observed (Table 3). The NNT in 5 mg/h and 15 mg/h group were 18.7 and 8.8 respectively.

In our assessment of the funnel plot of each meta-analysis, no evidence for publication bias was indicated.

**Discussion**

Since its first isolation from cultured porcine aortic endothelial cells, the critical role of ET-1 in vasospasm has been well-acknowledged, with several ET-receptor antagonists investigated [16]. Kramer et al [17] have conducted a meta-analysis of ET-receptor antagonists in aSAH, including another mixed ETA/B antagonist TAK-004, which was a nonselective ET-receptor antagonist that could diminish the magnitude of ET-1 blockade. The ETB receptor antagonist had been inferred of limited value for vasospasm [16,18]. Besides, the CONSCIOUS-2,3 trials were not included.

The main findings of our meta-analysis were as follows: First, clazosentan was superior to placebo in reducing the occurrence of...
vasospasm may contribute to DIND and poor outcome, vasospasm-related lesions [21]. Several processes other than interobserver variability in attributing CT hypodensities to CONSCIOUS-1 trial suggested that there was considerable could still be subjective. In fact, a post hoc analysis of a new hypodensity in CT scan could be attributed to vasospasm centrally reviewed in CONSCIOUS trials, the decision whether it is explained the discrepancies, except the study limitations listed it is instructive to investigate the potential causes that may render the studies a “failure of randomization”, in terms of selecting patients, and the prognostic baseline characteristics were well-balanced. The timing and duration of clazosentan were similar. Besides, similar criteria of outcomes were implemented. However, several limitations of our study have to be acknowledged. The number of the trials included might be relatively small, with 3 of the 4 analyzed studies designed and implemented by one group, thus decreasing the heterogeneity of the data sources while increasing the internal validity. The sample size, ranging from 32 to 1147, might be too small to show a statistically significant effect on clinical outcome. It has been estimated that more than 5,000 patients are needed to show a treatment effect size of 50% on the mRS 3 months after aSAH [19]. The small amount of patients may render the studies a “failure of randomization”, in terms of imbalance between various prognostic factors. For example, females nearly doubled males in all the trials. Notably, it has been suggested that females are associated with an increased risk of angiographic vasospasm [20]. Our pooling data suggested that female patients with aSAH had a significant reduction of vasospasm-related M/M, which might be criticized for the imbalanced gender at baseline. Moreover, not all the data we concerned were reported in the trials. For example, only 2 trials reported the incidence of angiographic vasospasm. The earliest trial was absent in the incidence of DIND with incomplete follow-up information [4].

Our meta-analysis showed no effect of clazosentan on reducing NCI, mortality or improving the functional outcome. It is instructive to investigate the potential causes that may explain the discrepancies, except the study limitations listed before. Though it was praiseworthy that the results of DCI were centrally reviewed in CONSCIOUS trials, the decision whether a new hypodensity in CT scan could be attributed to vasospasm could still be subjective. In fact, a post hoc analysis of CONSCIOUS-1 trial suggested that there was considerable interobserver variability in attributing CT hypodensities to vasospasm-related lesions [21]. Several processes other than vasospasm may contribute to DIND and poor outcome, including microthrombolism/embolism, impaired cerebral auto-regulation, delayed axonal degeneration, impaired stress response, clusters of spreading depolarizations, and perforator occlusion attributed to the surgical procedures of clipping or coiling [22,23,24,25,26]. The effect of clazosentan has been targeted on large vessel vasospasm, with little known effects on microcirculation. Large-vessel narrowing may not have a major impact on brain circulation in the presence of autoregulatory vasodilation of distal arterioles or in the presence of collateral flow [7,27]. Besides, clazosentan has been experimentally proved useless in preventing neuronal injury or microthromboembolism [28]. Rescue therapy was more frequently seen in the placebo group, which might provide a positive effect on outcome, thus obscuring the results [6]. Additionally, given a marked increasing of AEs in the clazosentan group, the therapeutic benefits might be counterbalanced [7]. All the 4 trials permitted the use of oral nimodipine which might interact with clazosentan and masked its benefits [6]. Further more, the functional outcome was measured by GOSE, which was noted to lack specificity in detecting subtle yet meaningful changes in cognition or functioning. In fact, a post hoc analysis has included the scales related to quality of life in patients with aSAH, demonstrating that vasospasm was associated with poor cognition and greater inpatient healthcare resource use [29].

Dose, AEs, and timing of clazosentan remain subjects of intense debate. Clazosentan in 15 mg/h seemed more favorable in reducing vasospasm related M/M compared with lower dose. Additionally, there was no statistically difference in the occurrence of AEs in different doses. Compared with placebo, clazosentan was with an increased risk of AEs. However, these AEs, were not only commonly seen in all patients with aSAH, but also manageable and not considered serious [5,13,16]. Moreover, although clazosentan was administered within 56 h up to 14 days after aSAH in all the trials, it has not been validated yet whether it was used timely. On one hand, considering cerebral vasospasm occurs most frequently 7 to 10 days after aneurysm rupture [1], a late use with a shorter course (7–10 d) might be more effective with the decreasing of AEs [14]. On the other hand, it was argued that clazosentan might work better if administered in the first hours after aSAH, given the effect on reversing acute decreasing cerebral perfusion pressure [30].

Conclusions

Our pooling data support the view that clazosentan is probably effective in the prevention of angiographic cerebral vasospasm, vasospasm-related DIND, vasospasm related M/M, and rescue therapy. However, current evidences do not support benefits of clazosentan in reducing NCI, all-cause mortality or improving functional outcome. Thus, it should be cautious to translate the effects of clazosentan on vasospasm into a clinical benefit. Given the various limitations in previous studies, further researches are necessary to fully understand the potential of clazosentan.
References

1. Connolly ES Jr, Rabinstein AA, Carhuapoma JR, Derdeyn CP, Dion J, et al. (2012) Guidelines for the Management of Aneurysmal Subarachnoid Hemorrhage: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke 43: 1711–1737.

2. Macdonald RL, Pluta RM, Zhang JH (2007) Cerebral vasospasm after subarachnoid hemorrhage: the emerging revolution. Nat Clin Pract Neurol 3: 256–263.

3. Barth M, Capelle HH, Munch E, Thome G, Fieller F, et al. (2007) Effects of the selective endothelin a (ETA) receptor antagonist Clazosentan on cerebral perfusion and cerebral oxygenation following severe subarachnoid hemorrhage: Preliminary results from a randomized clinical series. Acta Neurochirurgica 149: 911–918.

4. Vajkoczy P, Meyer B, Weidauer S, Raabe A, Thome C, et al. (2005) Clazosentan (ANV-034343), a selective endothelin A receptor antagonist, in the prevention of cerebral vasospasm following severe aneurysmal subarachnoid hemorrhage: Results of a randomized, double-blind, placebo-controlled, multicenter Phase IIa study. J Neurosurg 103: 9–17.

5. Macdonald RL, Kassell NF, Mayer S, Ruefenacht D, Schmiedek P, et al. (2008) Clazosentan to overcome neurological ischemia and infarction occurring after subarachnoid hemorrhage (CONSCIOUS-1): Randomized, double-blind, placebo-controlled phase 2 dose-finding trial. Stroke 39: 3015–3021.

6. Macdonald RL, Higashida RT, Keller E, Mayer SA, Molyneux A, et al. (2012) Randomized trial of clazosentan in patients with aneurysmal subarachnoid hemorrhage undergoing endovascular coiling. Stroke 43: 1463–1469.

7. Macdonald RL, Higashida RT, Keller E, Mayer SA, Molyneux A, et al. (2011) Clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid haemorrhage undergoing surgical clipping: A randomized, double-blind, placebo-controlled phase 3 trial (CONSCIOUS-2). Lancet Neurol 10: 618–625.

8. Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6: e1000097.

9. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, et al. (1996) Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials 17: 1–12.

10. Vergouwen MD, Vermeulen M, van Gijn J, Rinkel GJ, Wijdicks EF, et al. (2010) Definition of delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage as an outcome event in clinical trials and observational studies: proposal of a multidisciplinary research group. Stroke 41: 2391–2395.

11. Vergouwen MD (2011) Vasospasm versus delayed cerebral ischemia as an outcome event in clinical trials and observational studies. NeuroCrit Care 15: 308–311.

12. Barnett B, Bond M (1975) Assessment of outcome after severe brain damage. Lancet 1: 480–484.

13. Suarez JI, Tarr RW, Selman WR (2006) Aneurysmal subarachnoid hemorrhage. N Engl J Med 354: 387–396.

14. Wong GK, Poon WS (2011) Clazosentan for patients with subarachnoid haemorrhage: lessons learned. Lancet Neurol 10: 871; author reply 871–872.

15. van Giersbergen PL, Dingemans J (2007) Tolerability, pharmacokinetics, and pharmacodynamics of clazosentan, a parenteral endothelin receptor antagonist. Eur J Clin Pharmacol 63: 151–158.

16. Chow M, Dumont AS, Kassell NF, Seifert V, Zimmermann M, et al. (2002) Endothelin receptor antagonists and cerebral vasospasm: An update. Neurosurgery 51: 1333–1342.

17. Kramer A, Fletcher J (2009) Do endothelin-receptor antagonists prevent delayed neurological deficits and poor outcomes after aneurysmal subarachnoid hemorrhage?: A meta-analysis. Stroke 40: 3403–3406.

18. Vatter H, Konczalla J, Weidauer S, Preibisch C, Raabe A, et al. (2007) Characterization of the endothelin-B receptor expression and vasomotor function during experimental cerebral vasospasm. Neurosurgery 60: 1100–1108; discussion 1108–1109.

19. Kreiter KT, Mayer SA, Howard G, Knuppertz V, Bodigee D, et al. (2009) Sample size estimates for clinical trials of vasospasm in subarachnoid hemorrhage. Stroke 40: 2362–2367.

20. Rydlefs M, Enblad P, Ronne-Engstrom E, Persson L, Bodigee D, et al. (2010) Patient age and vasospasm after subarachnoid hemorrhage. Neurosurgery 67: 911–917.

21. Ibrahim GM, Weidauer S, Macdonald RL (2011) Interobserver variability in the interpretation of computed tomography following aneurysmal subarachnoid hemorrhage. J Neurosurg 115: 1191–1196.

22. Eminan N, Vergouwen MD, Bodigee D, Macdonald RL (2011) Effect of pharmaceutical treatment on vasospasm, delayed cerebral ischemia, and clinical outcome in patients with aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis. J Cereb Blood Flow Metab 31: 1443–1451.

23. Crowley RW, Medel R, Dumont AS, Bodigee D, Kassell NF, et al. (2011) Angiographic vasospasm is strongly correlated with cerebral infarction after subarachnoid hemorrhage. Stroke 42: 919–923.

24. Wotzitz J, Desier FP, Hecht N, Fuß I, Sandow N, et al. (2012) Delayed cerebral ischemia and spreading depolarization in absence of angiographic vasospasm after subarachnoid hemorrhage. J Cereb Blood Flow Metab 32: 203–212.

25. Vergouwen MD, van Geloven N, de Haan RJ, Kruyt ND, Vermeulen M, et al. (2010) Increased cortisol levels are associated with delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage. Neurocrit Care 12: 342–345.

26. Rabinstein AA (2011) Secondary brain injury after aneurysmal subarachnoid hemorrhage: more than vasospasm. Lancet Neurol 10: 593–595.

27. Dhar R, Scalmani MT, Blackburn S, Zazulia AR, Videen T, et al. (2012) Relationship Between Angiographic Vasospasm and Regional Hypoperfusion in Aneurysmal Subarachnoid Hemorrhage. Stroke 43: 1780–1794.

28. Sabri M, Ai J, MacDonald RL (2011) Dissemination of vasospasm and secondary effects of experimental subarachnoid hemorrhage by clazosentan. Stroke 42: 1454–1460.

29. MacDonald RL, Hunsche E, Vermeulen M, van Gijn J, Kruyt ND, et al. (2010) Increased cortisol levels are associated with delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage. Neurocrit Care 12: 342–345.

30. Schubert GA, Schilling L, Thome C (2008) Clazosentan, an endothelin receptor antagonist, prevents early hypoperfusion during the acute phase of massive experimental subarachnoid hemorrhage: a laser Doppler flowmetry study in rats. J Neurosurg 109: 1134–1140.

Author Contributions

Conceived and designed the experiments: XW YML CGH. Performed the experiments: XW YML QWL YCL LJH. Analyzed the data: XW YML QWL CGH. Contributed reagents/materials/analysis tools: CGH LJH. Wrote the paper: XW YML CGH LJH.

Meta-Analysis of Clazosentan Treatment in SAH